Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study

Blood (2021) 138 (Supplement 1): 633.

https://doi.org/10.1182/blood-2021-148369

Published: 2021

Journal Articles

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Hélène Deutsch, MD, Andre Baruchel, Joelle Guilhot, PhD, Arnaud Petit, MD PhD, Thierry Leblanc, MD, Yves Bertrand, MD, Brigitte Nelken, MD, Catherine Paillard, MD PhD, Cécile Verite, MD, Yves Réguerre, MD, Francoise Mechinaud, MD FRACP, Francois Guilhot, MD, Frederic Millot

Blood (2019) 134 (Supplement_1): 4147.

https://doi.org/10.1182/blood-2019-124060

Published: 2019

Journal Articles

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Delphine Rea, MD, Franck E Nicolini, MDPhD, Michel Tulliez, MD, Philippe Rousselot, MDPhD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, Francois Guilhot, MD, Joelle Guilhot, PhD, Agnès Guerci, MD PhD, Martine Escoffre-Barbe, MD, Laurence Legros, MD PhD, Bruno Villemagne, MD, Gaëlle Guillerm, MD, Marie-Pierre Noel, MD, Valerie Coiteux, MD, Jean-Michel Pignon, MD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 30.

https://doi.org/10.1182/blood-2019-124408

Published: 2019

Journal Articles

Oral CHOP-like Chemotherapy in Elderly Patients with High-Grade Non Hodgkin B Cell Lymphoma

Stephanie Guidez, Cecile Tomowiak, MD, Isabelle Princet, MD, Brigitte Dreyfus, MD, Gaelle Olivier, MD, Emmanuel Fleck, MD, Anne Corby, MD, Carine Motard, Antoine Machet, MD, Celine Debiais, MD, Xavier Leleu, MD PhD, Joelle Guilhot, PhD, Vincent Delwail, MD

Blood (2018) 132 (Supplement 1): 4231.

https://doi.org/10.1182/blood-2018-99-115379

Published: 2018

Journal Articles

The Evaluation of Residual Disease By Digital PCR, and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after for Stopping Imatinib First-Line in Chronic Phase CML Patients: Results of the STIM2 Study.

Franck Emmanuel Nicolini, MD PhD, Stephanie Dulucq, PhD, Joelle Guilhot, PhD, Gabriel Etienne, MD PhD, Francois-Xavier Mahon, MD PhD

Blood (2018) 132 (Supplement 1): 462.

https://doi.org/10.1182/blood-2018-99-113029

Published: 2018

Journal Articles

Advanced Phases at Diagnosis of Childhood Chronic Myeloid Leukemia : The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study)

Frédéric Millot, Joelle Guilhot, PhD, Meinolf Suttorp, MD PhD, Natacha Maledon, Meral Günes Adalet, MD, Petr Sedlacek, MD, Eveline S. de Bont, MD, Chi Kong Li, MD, Krzysztof Kalwak, MD, Birgitte Lausen, MD, Gordana Jakovljevic, MD, Michael Dworzak, MD, Andrea Hraskova, MD, Barbara De Moerloose, MD PhD, Roula Farah, MD, Andrea Biondi, MD, Andre Baruchel, MD

Blood (2017) 130 (Supplement 1): 316.

https://doi.org/10.1182/blood.V130.Suppl_1.316.316

Published: 2017

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

Phase 1/2 Study of Orociep All Oral Regimen with Idarubicin, Cyclophosphamide, Etoposide, Prednisolone in Combination to Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non Hodgkin Lymphoma. Final Analysis

Stephanie Guidez, Laurence lacotte-Thierry, Cecile Tomowiak, MD, Antoine Machet, Carine Motard, Anthony Levy, Cécile Gruchet, Florence Sabirou, Arthur Bobin, Niels Moya, Thomas Systchenko, Jocelyn Barrier, MD, Carine le Du, Emmanuel Fleck, MD, Diane Chuillet-Moreau, Michele Chabin, Xavier Leleu, MD PhD, Joelle Guilhot, PhD, Vincent Delwail, MD

Blood (2017) 130 (Supplement 1): 5207.

https://doi.org/10.1182/blood.V130.Suppl_1.5207.5207

Published: 2017

Journal Articles

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Markus Pfirrmann, Francois-Xavier Mahon, MD PhD, Joelle Guilhot, PhD, Johan Richter, MD PhD, Francis J. Giles, MD MB, FRCPath, Andreas Hochhaus, MD, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Giuseppe Saglio, MD PhD, Weiping Deng, Darshan Dalal, MPH, MD PhD, Susanne Saussele, MD

Blood (2017) 130 (Supplement 1): 1601.

https://doi.org/10.1182/blood.V130.Suppl_1.1601.1601

Published: 2017

Journal Articles

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Blood (2017) 129 (7): 846–854.

https://doi.org/10.1182/blood-2016-09-742205

Published: 2017

Journal Articles

A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML

Ingmar Glauche, PhD, Hendrik Liebscher, Christoph Baldow, Matthias Kuhn, Philipp Schulze, Tom Haehnel, Astghik Voskanyan, PhD, Joelle Guilhot, PhD, Stéphanie Dulucq, PhD, Nikolas von Bubnoff, MD, Susanne Saussele, MD, Satu Mustjoki, MD PhD, Philipp J. Jost, MD, Francois Guilhot, MD PhD, François-Xavier Mahon, MD PhD, Ingo Roeder, PhD

Blood (2016) 128 (22): 3099.

https://doi.org/10.1182/blood.V128.22.3099.3099

Published: 2016

Journal Articles

Prognostic Discrimination of Children and Adolescents with Chronic Myeloid Leukemia Based on the EUTOS Long Term Survival (ELTS) Score

Frédéric Millot, MD, Joelle Guilhot, PhD, Meinolf Suttorp, MD PhD, Adalet Meral Güneş, MD, Petr Sedlacek, MD, Evelina S De Bont, MD PhD, Chi Kong Li, MBBS, MD, Krzysztof Kalwak, MD, Birgitte Lausen, Srdjana Culic, MD, Barbara De Moerloose, MD, Andrea Biondi, MD, Andre Baruchel, MD PhD

Blood (2016) 128 (22): 626.

https://doi.org/10.1182/blood.V128.22.626.626

Published: 2016

Journal Articles

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

Blood (2016) 128 (22): 787.

https://doi.org/10.1182/blood.V128.22.787.787

Published: 2016

Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Blood (2016) 128 (22): 789.

https://doi.org/10.1182/blood.V128.22.789.789

Published: 2016

Journal Articles

Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort

Marc G Berger, MD PhD Professor, Bruno Pereira, PhD, Charlotte Oris, PhD, Sandrine Saugues, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Laurence Legros, MD, Martine Escoffre-Barbe, Franck E. Nicolini, MD PhD, Philippe Rousselot, MD PhD Professor, Delphine Rea, MD PhD, Joelle Guilhot, PhD, Marie Zénut, MD PhD, Agnès Guerci, MD PhD, Stephane Giraudier, MD PhD Professor, Francois-Xavier Mahon, MD PhD Professor

Blood (2015) 126 (23): 137.

https://doi.org/10.1182/blood.V126.23.137.137

Published: 2015

Journal Articles

Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)

Blood (2015) 126 (23): 134.

https://doi.org/10.1182/blood.V126.23.134.134

Published: 2015

Journal Articles

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Blood (2015) 126 (23): 343.

https://doi.org/10.1182/blood.V126.23.343.343

Published: 2015

Journal Articles

Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients

Gabriel Etienne, MD PhD, Delphine Rea, MD PhD, Joelle Guilhot, PhD, Francois Guilhot, MD, Françoise Huguet, MD, Laurence Legros, MD, Franck E. Nicolini, MD PhD, Aude Charbonnier, Agnes Guerci, MD, Bruno R. Varet, MD, Philippe Rousselot, MD PhD Professor, Francois Xavier Mahon, MD PhD

Blood (2015) 126 (23): 345.

https://doi.org/10.1182/blood.V126.23.345.345

Published: 2015

Journal Articles

Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)

Frédéric Millot, Joelle Guilhot, PhD, Meinolf Suttorp, Prof. Dr., Anne Sophie Meunier, MD, Gunes Adalet Meral, MD, Petr Sedlacek, MD PhD, Eveline de Bont, MD PhD, Chi Kong Li, MD, Krzysztof Kalwak, Birgitte Lausen, Srdjana Culic, Barbara De Moerloose, MD PhD, Andrea Biondi, Prof, MD, Andre Baruchel, MD

Blood (2015) 126 (23): 1576.

https://doi.org/10.1182/blood.V126.23.1576.1576

Published: 2015

Journal Articles

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Blood (2015) 126 (23): 2780.

https://doi.org/10.1182/blood.V126.23.2780.2780

Published: 2015

NARROW

FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Oral CHOP-like Chemotherapy in Elderly Patients with High-Grade Non Hodgkin B Cell Lymphoma

The Evaluation of Residual Disease By Digital PCR, and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after for Stopping Imatinib First-Line in Chronic Phase CML Patients: Results of the STIM2 Study.

Advanced Phases at Diagnosis of Childhood Chronic Myeloid Leukemia : The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study)

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Phase 1/2 Study of Orociep All Oral Regimen with Idarubicin, Cyclophosphamide, Etoposide, Prednisolone in Combination to Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non Hodgkin Lymphoma. Final Analysis

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML

Prognostic Discrimination of Children and Adolescents with Chronic Myeloid Leukemia Based on the EUTOS Long Term Survival (ELTS) Score

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort

Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients

Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only